AAV8-FGF21 / AstraZeneca - LARVOL DELTA

AAV-FGF21 reverses type 2 diabetes and improves cardiac insulin resistance in db/db mice (EASD 2025) - "Our findings suggest that chronic exposure of pharmacological levels of FGF21 (176±39ng/ml, day 14 post dosing) produced by AAV8-FGF21 suppress weight gain and diabetes, attenuate cardiac insulin resistance, and ultimately reduce the development of cardiac hypertrophy in db/db mice."

Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • FGF21